Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir.
Journal
Alimentary pharmacology & therapeutics
ISSN: 1365-2036
Titre abrégé: Aliment Pharmacol Ther
Pays: England
ID NLM: 8707234
Informations de publication
Date de publication:
02 May 2024
02 May 2024
Historique:
revised:
04
03
2024
received:
09
02
2024
accepted:
14
04
2024
medline:
2
5
2024
pubmed:
2
5
2024
entrez:
2
5
2024
Statut:
aheadofprint
Résumé
Sofosbuvir, velpatasvir and voxilaprevir (SOF/VEL/VOX) is the recommended rescue therapy for patients with chronic hepatitis C infection who fail direct-acting antivirals (DAAs). Data are limited on the effectiveness of this treatment after the current first-line therapies. Our aim was to analyse the effectiveness and safety of SOF/VEL/VOX among patients failing sofosbuvir/velpatasvir (SOF/VEL) or glecaprevir/pibrentasvir (GLE/PIB). Retrospective multicentre study (26 Spanish hospitals), including chronic hepatitis C patients unsuccessfully treated with SOF/VEL or GLE/PIB, and retreated with SOF/VEL/VOX ± ribavirin for 12 weeks between December 2017 and December 2022. In total, 142 patients included: 100 (70.4%) had failed SOF/VEL and 42 (29.6%) GLE/PIB. Patients were mainly men (84.5%), White (93.9%), with hepatitis C virus genotype (GT) 3 (49.6%) and 47.2% had liver cirrhosis. Sustained virological response (SVR) was evaluated in 132 patients who completed SOF/VEL/VOX and were followed 12 weeks after end of treatment; 117 (88.6%) achieved SVR. There were no significant differences in SVR rates according to initial DAA treatment (SOF/VEL 87.9% vs. GLE/PIB 90.2%, p = 0.8), cirrhosis (no cirrhosis 90% vs. cirrhosis 87.1%, p = 0.6) or GT3 infection (non-GT3 91.9% vs. GT3 85.5%, p = 0.3). However, when considering the concurrent presence of SOF/VEL treatment, cirrhosis and GT3 infection, SVR rates dropped to 82.8%. Ribavirin was added in 8 (6%) patients, all achieved SVR. SOF/VEL/VOX is an effective rescue therapy for failures to SOF/VEL or GLE/PIB, with an SVR of 88.6%. Factors previously linked to lower SVR rates, such as GT3 infection, cirrhosis and first-line therapy with SOF/VEL were not associated with lower SVRs.
Sections du résumé
BACKGROUND
BACKGROUND
Sofosbuvir, velpatasvir and voxilaprevir (SOF/VEL/VOX) is the recommended rescue therapy for patients with chronic hepatitis C infection who fail direct-acting antivirals (DAAs). Data are limited on the effectiveness of this treatment after the current first-line therapies. Our aim was to analyse the effectiveness and safety of SOF/VEL/VOX among patients failing sofosbuvir/velpatasvir (SOF/VEL) or glecaprevir/pibrentasvir (GLE/PIB).
METHODS
METHODS
Retrospective multicentre study (26 Spanish hospitals), including chronic hepatitis C patients unsuccessfully treated with SOF/VEL or GLE/PIB, and retreated with SOF/VEL/VOX ± ribavirin for 12 weeks between December 2017 and December 2022.
RESULTS
RESULTS
In total, 142 patients included: 100 (70.4%) had failed SOF/VEL and 42 (29.6%) GLE/PIB. Patients were mainly men (84.5%), White (93.9%), with hepatitis C virus genotype (GT) 3 (49.6%) and 47.2% had liver cirrhosis. Sustained virological response (SVR) was evaluated in 132 patients who completed SOF/VEL/VOX and were followed 12 weeks after end of treatment; 117 (88.6%) achieved SVR. There were no significant differences in SVR rates according to initial DAA treatment (SOF/VEL 87.9% vs. GLE/PIB 90.2%, p = 0.8), cirrhosis (no cirrhosis 90% vs. cirrhosis 87.1%, p = 0.6) or GT3 infection (non-GT3 91.9% vs. GT3 85.5%, p = 0.3). However, when considering the concurrent presence of SOF/VEL treatment, cirrhosis and GT3 infection, SVR rates dropped to 82.8%. Ribavirin was added in 8 (6%) patients, all achieved SVR.
CONCLUSION
CONCLUSIONS
SOF/VEL/VOX is an effective rescue therapy for failures to SOF/VEL or GLE/PIB, with an SVR of 88.6%. Factors previously linked to lower SVR rates, such as GT3 infection, cirrhosis and first-line therapy with SOF/VEL were not associated with lower SVRs.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.
Références
Lampertico P, Carrión JA, Curry M, Turnes J, Cornberg M, Negro F, et al. Real‐world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: a meta‐analysis. J Hepatol. 2020;72(6):1112–1121.
Wei L, Lim SG, Xie Q, Văn KN, Piratvisuth T, Huang Y, et al. Sofosbuvir–velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single‐arm, open‐label, phase 3 trial. Lancet Gastroenterol Hepatol. 2019;4(2):127–134.
Esteban R, Pineda JA, Calleja JL, Casado M, Rodríguez M, Turnes J, et al. Efficacy of sofosbuvir and velpatasvir, with and without ribavirin, in patients with hepatitis C virus genotype 3 infection and cirrhosis. Gastroenterology. 2018;155(4):1120–1127.e4.
Pawlotsky JM, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, et al. EASL recommendations on treatment of hepatitis C: final update of the series. J Hepatol. 2020;73(5):1170–1218.
Chung RT, Ghany MG, Kim AY, Marks KM, Naggie S, Vargas HE, et al. Hepatitis C guidance 2018 update: AASLD‐IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis. 2018;67(10):1477–1492.
Bourlière M, Gordon SC, Flamm SL, Cooper CL, Ramji A, Tong M, et al. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med. 2017;376(22):2134–2146.
Papaluca T, Roberts SK, Strasser SI, Stuart KA, Farrell G, Macquillan G, et al. Efficacy and safety of sofosbuvir/velpatasvir/voxilaprevir for hepatitis C virus (HCV) NS5A‐inhibitor experienced patients with difficult to cure characteristics. Clin Infect Dis. 2021;73(9):E3288–E3295.
Belperio PS, Shahoumian TA, Loomis TP, Backus LI. Real‐world effectiveness of sofosbuvir/velpatasvir/voxilaprevir in 573 direct‐acting antiviral experienced hepatitis C patients. J Viral Hepat. 2019;26(8):980–990.
Llaneras J, Riveiro‐Barciela M, Lens S, Diago M, Cachero A, García‐Samaniego J, et al. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs. J Hepatol. 2019;71(4):666–672.
Degasperi E, Spinetti A, Lombardi A, Landonio S, Rossi MC, Pasulo L, et al. Real‐life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure. J Hepatol. 2019;71(6):1106–1115.
Smith DA, Bradshaw D, Mbisa JL, Manso CF, Bibby DF, Singer JB, et al. Real world SOF/VEL/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy. J Viral Hepat. 2021;28(9):1256–1264.
Liu CH, Peng CY, Liu CJ, Chen CY, Lo CC, Tseng KC, et al. Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct‐acting antivirals: a real‐world multicenter cohort in Taiwan. Hepatol Int. 2023;17(2):291–302.
Devan P, Tiong KLA, Neo JE, Mohan BP, Wijarnpreecha K, Tam YCS, et al. Treatment outcomes of sofosbuvir/velpatasvir/voxilaprevir in direct‐acting antiviral‐experienced hepatitis C virus patients: a systematic review and meta‐analysis. Viruses. 2023;15(7):1489.
Graf C, D'Ambrosio R, Degasperi E, Paolucci S, Llaneras J, Vermehren J, et al. Real‐world effectiveness of voxilaprevir/velpatasvir/sofosbuvir in patients following DAA failure. JHEP Rep. 2024;6(3):100994.
Asante‐Appiah E, Curry S, McMonagle P, Ingravallo P, Chase R, Nickle D, et al. Antiviral activity and resistance analysis of NS3/4A protease inhibitor grazoprevir and NS5A inhibitor elbasvir in hepatitis C virus GT4 replicons. Antimicrob Agents Chemother. 2017;61(7):00363–17.
Kyuregyan KK, Kichatova VS, Karlsen AA, Isaeva OV, Solonin SA, Petkov S, et al. Factors influencing the prevalence of resistance‐associated substitutions in NS5A protein in treatment‐naive patients with chronic hepatitis C. Biomedicine. 2020;8(4):1–20.
Wyles DL. Resistance to DAAs: when to look and when it matters. Curr HIV/AIDS Rep. 2017;14(6):229–237.
Li Z, Chen Z, Wei LH, Ren H, Hu P. Prevalence of hepatitis C virus‐resistant association substitutions to direct‐acting antiviral agents in treatment‐naïve hepatitis C genotype 1b‐infected patients in western China. Infect Drug Resist. 2017;10:377–392.
El‐Kassas M, Emadeldeen M, Hassany M, Esmat G, Gomaa AA, El‐Raey F, et al. A randomized‐controlled trial of SOF/VEL/VOX with or without ribavirin for retreatment of chronic hepatitis C. J Hepatol. 2023;79(2):314–320.
Center for Drug Evaluation and Research, U.S. Food and Drug Administration. Risk of liver injury with certain HCV drugs in advanced liver disease [Internet]. 2024 https://www.fda.gov/drugs/drug‐safety‐and‐availability/fda‐warns‐about‐rare‐occurrence‐serious‐liver‐injury‐use‐hepatitis‐c‐medicines‐mavyret‐zepatier‐and
Roncero C, Villegas JL, Martínez‐Rebollar M, Buti M. The pharmacological interactions between direct‐acting antivirals for the treatment of chronic hepatitis c and psychotropic drugs. Expert Rev Clin Pharmacol. 2018;11(10):999–1030.
Dietz J, Di Maio VC, de Salazar A, Merino D, Vermehren J, Paolucci S, et al. Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy. J Hepatol. 2021;74(4):801–810.